Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.
Martin R StocklerAndrew J MartinIan D DavisHaryana M DhillonStephen D BegbieKim N ChiSimon ChowdhuryXanthi CoskinasMark FrydenbergWendy E HagueLisa G HorvathAnthony M JoshuaNicola J LawrenceGavin M MarxJohn McCaffreyRay McDermottMargaret McJannettScott A NorthFrancis ParnisWendy R ParulekarDavid W PookM Neil ReaumeShahneen SandhuAlvin TanThean Hsiang TanAlastair ThomsonFrancisco Emilio Vera-BadilloScott G WilliamsDiana G WinterSonia YipAlison Y ZhangRobert R ZielinskiChristopher J Sweeneynull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Enzalutamide was associated with worsening of self-reported fatigue, cognitive function, and physical function, but not OHQL. Enzalutamide was associated with improved deterioration-free survival for OHQL, physical function, and cognitive function because delays in disease progression outweighed early deteriorations in these aspects of HRQL.